Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
39.42
-0.03 (-0.08%)
At close: Sep 12, 2025, 4:00 PM EDT
39.75
+0.33 (0.84%)
After-hours: Sep 12, 2025, 6:03 PM EDT
Harrow Revenue
Harrow had revenue of $63.74M in the quarter ending June 30, 2025, with 30.25% growth. This brings the company's revenue in the last twelve months to $227.66M, up 47.69% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$227.66M
Revenue Growth
+47.69%
P/S Ratio
6.24
Revenue / Employee
$595,971
Employees
382
Market Cap
1.46B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HROW News
- 1 day ago - Harrow: Buy A Blend Of Value And Growth - Seeking Alpha
- 4 days ago - Harrow: A Classical GARP Stock - Seeking Alpha
- 5 days ago - Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 - GlobeNewsWire
- 5 days ago - Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 - GlobeNewsWire
- 4 weeks ago - Harrow's Ambitious Guidance Puts It In The Proving Ground - Seeking Alpha
- 4 weeks ago - Harrow: Exciting Times In Store - Seeking Alpha
- 4 weeks ago - Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Harrow Announces Second-Quarter 2025 Financial Results - GlobeNewsWire